Amidine derivatives for treating amyloidosis
View Patent ↗The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:
1. A method of treating a disease selected from the group consisting of Alzheimer's disease, Down's syndrome, Mild Cognitive Impairment, age-related macular degeneration, and cerebral amyloid angiopathy in a subject in need thereof comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of
N-(6-aminoheptyl)-4-bromobenzamidine (compound #145),
4-bromo-N-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146),
N-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147),
N-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148),
N-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester (compound #149),
4,4′-(pentamethylenediamidino)di(p-bromobenzene) (compound #150),
4,4′-(nonamethylenediamidino)di(p-bromobenzene) (compound #151),
4,4′-(nonamethylenediamidino)di(p-methoxybenzene) (compound #152),
4-methoxy-N-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine (compound #153),
4,4′-(pentamethylenediamidino)di(p-methoxybenzene) (compound #154),
2,2′-(p-amidinophenylcarboxamido)-N,N-diethyl-p-amidinobenzamide (compound #155),
{4-[5-(p-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1H-imidazol-2-yl)-amine (compound #156),
4,4′-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158),
3,3′-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159),
4,4′-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and
pharmaceutically acceptable salts thereof.
2. The method according to claim 1 , wherein said compound is adapted to be administered orally.
3. The method according to claim 1 , where said subject is a human.
4. A chemical compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
5. A pharmaceutical composition comprising a compound according to claim 4 , and a pharmaceutically acceptable vehicle.
6. A pharmaceutical composition for the treatment of a disease selected from the group consisting of Alzheimer's disease, Down's syndrome, Mild Cognitive Impairment, age-related macular degeneration, and cerebral amyloid angiopathy comprising a therapeutically effective amount of a compound according to claim 4 .
7. A method for the treatment of Alzheimer's disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of
and pharmaceutically acceptable salts thereof.